



John F. Kamp, JD, PhD

Executive Director
Coalition for Healthcare Communication

Dr. John F. Kamp is Executive Director of the Coalition for Healthcare Communication, a drug marketing group with offices in New York City and Washington, DC. He is also of counsel with the law firm Wiley Rein LLP, and is a well-known advocate for First Amendment rights of individuals and corporations. His professional experience includes 10 years with the Washington office of the American Association of Advertising Agencies and nearly a decade in public policy positions at the Federal Communications Commission. Before moving to Washington, Dr. Kamp taught journalism at the University of Iowa and at Tulsa University.

Dr. Kamp is a frequent speaker at industry meetings on ethical, legal, and political issues surrounding drug marketing, and is recognized as an authority on these issues by the print and broadcast press. He serves on the public advisory committee of the American Academy of Family Physicians and education advisory boards of Wyeth and Genentech. He is on the editorial boards of the *Rx Compliance Report*, *Medical Marketing and Media*, and the *FDA Advertising and Promotion Manual*. Dr. Kamp is co-author (with Wayne Pines) of 3 books on compliance with FDA policy published by FDA News, including *DTC Advertising and Promotion: The Changing Environment*, published in January 2006. He is also a public member of the National Advertising Review Board, the self-regulation body of the advertising industry run by the National Better Business Bureau.

Dr. Kamp earned his bachelors degree at the University of Notre Dame, his doctorate from the University of Iowa and his juris doctorate at the University of Tulsa.

Disclosure: John Kamp is Executive Director of the Coalition for Healthcare Communication, a policy group with membership from health marketing trade associations and companies. Kamp has provided regulatory and strategic consulting and/or regulatory training for several marketing companies and drug and device companies. Kamp owns stock in companies in the drug and device industries, including Johnson & Johnson, Pfizer, Wyeth and Amylin, and in related communication and media companies, including McGraw-Hill, Omnicom and WPP Group. Kamp also serves as “of counsel” at Wiley, Rein, LLP, in Washington, DC.

Mr. Kamp is not an expert in the practice of medicine and does not make therapeutic recommendations for any specific drug, device or procedure. Thus, any discussion of medical practice, including “off label” use, will be only in the context of public policy, industry practice, and/or government regulation.